Areas of Special Interest in PsO

Slides:

Advertisements

Similar presentations

WEEK 1 You have 10 seconds to name…

Advertisements

Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: An Analysis of a Phase 3 Extension Trial in Psoriasis

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Tips Need to Consider When Organizing a College Event

Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

An Endocrinology Clinic in Dyslipidemia

PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.

Clinical Developments in Inflammatory Arthritis 2017

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Current and Emerging Treatments for IBD

At The Cutting Edge of Developments in the Management of Hyperkalemia

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

From Conference to Practice: Big Data in Psoriasis

PCP Perspectives Clinical Considerations in Hyperkalemia

Expert Insights on Psoriatic Arthritis From Washington, DC

What Has Been Tried and What Is True?

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Second Year Projects: Voyages of Exploration

Beyond Statin Therapy.

Psoriasis and Comorbidities Psoriasis and Cardiometabolic Comorbidities.

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

ماجستير إدارة المعارض من بريطانيا

Translating Atopic Dermatitis

HCV Protease Inhibitors in Clinical Practice

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in

Managing Adverse Events With New Oral Therapies in CLL

Evolving Treatment Landscape for PsA

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

New Data on Emerging Treatments for Psoriasis

Improving Outcomes in Psoriatic Arthritis

The Evolving Treatment Landscape in Atopic Dermatitis

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Shifting Currents in Hyperkalemia Management 2015 in Review

Shifting Currents in Hyperkalemia Management 2015 in Review

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

The Multifaceted Nature of Psoriasis Addressing Patients' Needs

CAD and HF Often Coexist

Ask the Psoriasis Expert

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Patient Questions and Expert Answers in Psoriasis:

HCV Protease Inhibitors in Clinical Practice

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Essential Updates for PsA: A Complex Disease to Manage

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Educational Objectives

New Paradigms in M0 CRPC.

Oral Therapies in MS.

New Lipid-Lowering Therapies

Targeting IL-23 for Therapeutic Longevity in Psoriasis

PCSK9 Inhibitors and Statin Intolerance

Understanding How IL-23p19 Inhibitors Work in Psoriasis

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Rheumatoid Arthritis.

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

Treatment Advances for RA

Program. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice.

PHOENIX I: PASI 75 Response After 12 Weeks

The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Psoriatic Arthritis.

Presentation transcript:

Areas of Special Interest in PsO

Genital PsO: Patients' Perspectives

Long-Term Efficacy With IL-17 Inhibitor Ixekizumab: UNCOVER-1

Long-Term Efficacy With IL-23p19 Inhibitor Guselkumab: VOYAGE-1

Adverse Events Through Week 56 (ECLIPSE)

IL-17 and IL-23p19 Inhibitors Are Effective in Areas of Special Interest

Risankizumab Withdrawal and Persistence of PASI 90 Response: IMMhance

Guselkumab Withdrawal and Persistence of PASI 90 Response: VOYAGE-2

Safety Profile of Guselkumab and Risankizumab

Abbreviations